EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants

Andy Sykes, Zhoupeng Zhang, Jana Skeete, Pradeep Sharma, Stephen Wilkinson, Ryan Bragg, Sasha McClain, Malin Gränfors, Isobel Leddin, Christopher Bailey, Bistra Kirova, Nand Singh und 2 weitere

Drug Metabolism and Disposition · 2026-07 · 54 (7) · 100342

DOI: 10.1016/j.dmd.2026.100342 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Metabolism and Disposition, 2026-07. Verfasst von Andy Sykes und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge, UK. Electronic address: andy.sykes@astrazeneca.com. Hauptthemen laut MEDLINE: Estrogen Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor AntagonistsHumansFemaleMiddle AgedAdministration, OralAgedFecesCarbon RadioisotopesHealthy VolunteersPostmenopauseAzetidinesIsoquinolines

Stichwörter der Autor:innen

Absorption, metabolism, and excretionCamizestrantOncologyPharmacokineticsSelective estrogen receptor degrader

Substanzen

Carbon RadioisotopesCarbon-14Estrogen Receptor AntagonistsAZD9833AzetidinesIsoquinolines

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge, UK. Electronic address: andy.sykes@astrazeneca.com.
  • Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
  • Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge, UK.
  • Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Early Chemical Development, Pharmaceutical Sciences, AstraZeneca, Cambridge, UK.
  • Late Development, Oncology R&D, AstraZeneca, Gaithersburg, Maryland.

Förderung

  • AstraZeneca PLC

Zitieren

APA

Sykes, A., Zhang, Z., Skeete, J., Sharma, P., Wilkinson, S., Bragg, R., McClain, S., Gränfors, M., Leddin, I., Bailey, C., Kirova, B., Singh, N., Vishwanathan, K., & Hariparsad, N. (2026). Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants. Drug Metabolism and Disposition, 54(7), 100342. https://doi.org/10.1016/j.dmd.2026.100342

Vancouver

Sykes A, Zhang Z, Skeete J, Sharma P, Wilkinson S, Bragg R, et al. Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants. Drug Metabolism and Disposition. 2026;54(7):100342. doi:10.1016/j.dmd.2026.100342

BibTeX
@article{Sykes2026,
  author = {Sykes, Andy and Zhang, Zhoupeng and Skeete, Jana and Sharma, Pradeep and Wilkinson, Stephen and Bragg, Ryan and McClain, Sasha and Gränfors, Malin and Leddin, Isobel and Bailey, Christopher and Kirova, Bistra and Singh, Nand and Vishwanathan, Karthick and Hariparsad, Niresh},
  title = {Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {7},
  pages = {100342},
  doi = {10.1016/j.dmd.2026.100342}
}
Kostenlos starten →